Covid19
Conditions
Keywords
DNA damage, Oxidative Stress, Inflammation
Brief summary
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic challenging health systems worldwide. While there is a clear correlation between oxidative stress markers and the severity of many viral diseases such as hepatitis C, for SARS-CoV clinical data is limited. The investigators aim at 1.) investigating DNA damage, oxidative stress, inflammation, and aging markers in COVID-19 patients and compare them with age and gender matched healthy controls and patients with influenza; and 2.) investigating all aforementioned parameters during cytokine storm via repeated blood sampling.
Interventions
OTHERNo intervention
Case-control design, one single investigation
Sponsors
SMZ-Ost Donauspital
University of Vienna
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Covid 19 group: Inclusion Criteria: * gender: female/male * age: ≥40 years * patients admitted at the emergency department * COVID-19 suspected patients * able to give written informed consent
Exclusion criteria
* children (≤ 18 years) and adults 19-39 years * not hospitalized, but confirmed COVID-19 patients (outpatients) * patients without definitive COVID-19 confirmation Control group: Inclusion criteria: * gender: female/male * age: ≥40 years * absence of severe illnesses/serious diseases * able to give written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DNA damage | Baseline | Compare DNA damage (% of DNA in the tail; measured by the comet assay) between hospitalized COVID-19 patients to influenza patients and healthy controls. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The investigators will consider oxidative stress marker | Baseline | Compare oxidative stress biomarker malondialdehyde, FRAP, GSH, GSSG (all µmol/L) and the ration GSH/GSSG between hospitalized COVID-19 patients to influenza patients and healthy controls. |
| The investigators will consider inflammatory marker | Baseline | Compare inflammatory marker Interleukin 1 (IL-1), IL-6, IL-8, IL-10, TNF-alpha (all rfU) and CRP (mg/dl) between hospitalized COVID-19 patients to influenza patients and healthy controls. |
| The investigators will consider further DNA damage parameter | Baseline | Compare other DNA damage endpoints measured with the comet assay (i.e. tail length, tail moment and damage index) between hospitalized COVID-19 patients to influenza patients and healthy controls. |
| The investigators will consider RDA and DNA gene expression | Baseline | Compare RNA and DNA gene expression between hospitalized COVID-19 patients to influenza patients and healthy controls. |
| The investigators will consider clinical biochemistry marker | Baseline | Compare clinical biochemistry (Total cholesterol (mg/dl), LDL-cholesterol (mg/dl), triglycerides (mg/dl), blood glucose (mg/dl), uric acid (mg/dl)) between hospitalized COVID-19 patients to influenza patients and healthy controls. |
| The investigators will consider the phenotypic age marker | Baseline | Compare the phenotypic age marker between hospitalized COVID-19 patients to influenza patients and healthy controls. |
Countries
Austria
Contacts
Primary ContactKarl-Heinz Wagner, PhD
Outcome results
None listed